Anatibant®, a selective non-peptide bradykinin B2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury-Reference-Cited by-同舟云学术

Anatibant®, a selective non-peptide bradykinin B2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury

Published:2009-04 Issue:2 Volume:454 Page:115-117
ISSN:0304-3940
Container-title:Neuroscience Letters
language:en
Short-container-title:Neuroscience Letters

Author:

Zweckberger Klaus,Plesnila Nikolaus

Publisher

Elsevier BV

Subject

General Neuroscience

Reference33 articles.

1. Origin and therapy of secondary brain damage;Baethmann;MMW Münchner Med. Wochenschr.,1982

2. Mediators of brain edema and secondary brain damage;Baethmann;Crit. Care Med.,1988

3. Pathogenesis of traumatic brain swelling: role of cerebral blood volume;Bouma;Acta Neurochir. (Suppl.),1998

4. ABC of major trauma. Head injuries;Bullock;BMJ,1990

5. B2 bradykinin receptor immunoreactivity in rat brain;Chen;J. Comp. Neurol.,2000

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bradykinin 2 Receptors Mediate Long-Term Neurocognitive Deficits After Experimental Traumatic Brain Injury;Journal of Neurotrauma;2024-06-27

2. THE NEUROENDOTHELIAL AXIS IN TRAUMATIC BRAIN INJURY: MECHANISMS OF MULTIORGAN DYSFUNCTION, NOVEL THERAPIES, AND FUTURE DIRECTIONS;Shock;2024-01-08

3. The Single-Dose Application of Interleukin-4 Ameliorates Secondary Brain Damage in the Early Phase after Moderate Experimental Traumatic Brain Injury in Mice;International Journal of Molecular Sciences;2023-08-14

4. Tackling Neuroinflammation After Traumatic Brain Injury: Complement Inhibition as a Therapy for Secondary Injury;Neurotherapeutics;2022-10-12

5. Size‐Selective Transfer of Lipid Nanoparticle‐Based Drug Carriers Across the Blood Brain Barrier Via Vascular Occlusions Following Traumatic Brain Injury;Small;2022-04-05